CN111643490B - 一种具有麦芽糖水解酶抑制活性的药物组合物及其应用 - Google Patents
一种具有麦芽糖水解酶抑制活性的药物组合物及其应用 Download PDFInfo
- Publication number
- CN111643490B CN111643490B CN202010530261.XA CN202010530261A CN111643490B CN 111643490 B CN111643490 B CN 111643490B CN 202010530261 A CN202010530261 A CN 202010530261A CN 111643490 B CN111643490 B CN 111643490B
- Authority
- CN
- China
- Prior art keywords
- diabetes
- trihydroxyacetophenone
- pharmaceutical composition
- maltose
- dnj
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 title claims abstract description 34
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 title claims abstract description 34
- 230000000694 effects Effects 0.000 title claims abstract description 26
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 20
- 230000005764 inhibitory process Effects 0.000 title description 19
- LXBIFEVIBLOUGU-JGWLITMVSA-N duvoglustat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O LXBIFEVIBLOUGU-JGWLITMVSA-N 0.000 claims abstract description 75
- LXBIFEVIBLOUGU-UHFFFAOYSA-N Deoxymannojirimycin Natural products OCC1NCC(O)C(O)C1O LXBIFEVIBLOUGU-UHFFFAOYSA-N 0.000 claims abstract description 37
- XIROXSOOOAZHLL-UHFFFAOYSA-N 2',3',4'-Trihydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C(O)=C1O XIROXSOOOAZHLL-UHFFFAOYSA-N 0.000 claims abstract description 34
- 239000003814 drug Substances 0.000 claims abstract description 34
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 27
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 14
- 108010028144 alpha-Glucosidases Proteins 0.000 claims description 15
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims description 8
- 102000016679 alpha-Glucosidases Human genes 0.000 claims description 7
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 7
- 208000001280 Prediabetic State Diseases 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 6
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000008280 blood Substances 0.000 abstract description 19
- 210000004369 blood Anatomy 0.000 abstract description 19
- 230000000291 postprandial effect Effects 0.000 abstract description 11
- 230000000857 drug effect Effects 0.000 abstract description 6
- 239000000758 substrate Substances 0.000 abstract description 4
- 239000004093 hydrolase inhibitor Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 26
- 102000004157 Hydrolases Human genes 0.000 description 14
- 108090000604 Hydrolases Proteins 0.000 description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 12
- 239000008103 glucose Substances 0.000 description 12
- 239000003112 inhibitor Substances 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 230000002195 synergetic effect Effects 0.000 description 9
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 8
- 235000008708 Morus alba Nutrition 0.000 description 8
- 240000000249 Morus alba Species 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 210000000813 small intestine Anatomy 0.000 description 6
- -1 sulfonylureas Chemical class 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 5
- 229930013930 alkaloid Natural products 0.000 description 5
- 230000001603 reducing effect Effects 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 4
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000004366 Glucose oxidase Substances 0.000 description 3
- 108010015776 Glucose oxidase Proteins 0.000 description 3
- 208000013016 Hypoglycemia Diseases 0.000 description 3
- 229960002632 acarbose Drugs 0.000 description 3
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical group O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 229940116332 glucose oxidase Drugs 0.000 description 3
- 235000019420 glucose oxidase Nutrition 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 2
- 229940123208 Biguanide Drugs 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- YZNNBIPIQWYLDM-HSUXUTPPSA-N Fagomine Chemical compound OC[C@H]1NCC[C@@H](O)[C@@H]1O YZNNBIPIQWYLDM-HSUXUTPPSA-N 0.000 description 2
- YZNNBIPIQWYLDM-ZLUOBGJFSA-N Fagomine Natural products OC[C@@H]1NCC[C@H](O)[C@H]1O YZNNBIPIQWYLDM-ZLUOBGJFSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- YZNNBIPIQWYLDM-UHFFFAOYSA-N L-fagomine Natural products OCC1NCCC(O)C1O YZNNBIPIQWYLDM-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- XHEFDIBZLJXQHF-UHFFFAOYSA-N fisetin Chemical compound C=1C(O)=CC=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 XHEFDIBZLJXQHF-UHFFFAOYSA-N 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
- 229940035436 maltitol Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000007410 oral glucose tolerance test Methods 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 150000003214 pyranose derivatives Chemical class 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000010902 straw Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 1
- HCEQQASHRRPQFE-UHFFFAOYSA-N 5-chloro-n-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-2-methoxybenzamide;3-(diaminomethylidene)-1,1-dimethylguanidine;hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N.COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 HCEQQASHRRPQFE-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- 241000218213 Morus <angiosperm> Species 0.000 description 1
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 229940054739 avandamet Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 235000011990 fisetin Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- 229940112611 glucovance Drugs 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 125000003071 maltose group Chemical group 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 229950004994 meglitinide Drugs 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 229940035732 metformin and rosiglitazone Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 description 1
- 235000007743 myricetin Nutrition 0.000 description 1
- 229940116852 myricetin Drugs 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- BGMYHTUCJVZIRP-GASJEMHNSA-N nojirimycin Chemical class OC[C@H]1NC(O)[C@H](O)[C@@H](O)[C@@H]1O BGMYHTUCJVZIRP-GASJEMHNSA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- SUFUKZSWUHZXAV-BTJKTKAUSA-N rosiglitazone maleate Chemical compound [H+].[H+].[O-]C(=O)\C=C/C([O-])=O.C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O SUFUKZSWUHZXAV-BTJKTKAUSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
一种具有麦芽糖水解酶抑制活性的药物组合物,包括2,3,4‑三羟基苯乙酮和1‑脱氧野尻霉素。本发明的药物组合物能更有效的降低餐后血糖,能够抑制以麦芽糖为底物麦芽糖水解酶活性,更少地使用麦芽糖水解酶抑制剂,因此可以提高药效,药物组合物具有开发为预防或治疗糖尿病药物的潜力。
Description
技术领域
本发明涉及一种具有麦芽糖水解酶抑制活性的药物组合物,属于医药生物领域。
背景技术
糖尿病是21世纪最严重的世界健康疾病之一,对人类健康带来了极大的危害。根据国际糖尿病联盟(IDF,International Diabetes Federation)的最新统计数字,截至2017年全球共有4.25亿人患有糖尿病,另有3.52亿人患有前驱糖尿病。每年约400万人死于糖尿病,应用于糖尿病的医疗开支约为7270亿美元,位列全部疾病的第二位。糖尿病患者人数近年来飞速增加,预计在2040年达到6.42 亿人。糖尿病可主要归类为1型(胰岛素依赖性糖尿病)、2型(非胰岛素依赖性糖尿病)和妊娠糖尿病,2型糖尿病是最常见的形式,占所有糖尿病患者的 90%以上,此外,当血糖高于正常血糖范围,而又低于糖尿病血糖范围的状态为糖尿病前期,也称为前驱糖尿病。前驱糖尿病是2型糖尿病的前期阶段,如果前驱糖尿病患者不改变其生活状态,超过70%的患者将会发展为2型糖尿病 (The Lancet,2012,379:2279-2290)。流行病学调查也显示,我国前驱糖尿病的患病率为35.7%。由糖尿病引起的一系列并发症常涉及多个器官,如血管损伤、动脉粥样硬化、常见感染和癌症的风险增加等,严重影响着患者的身心健康与生活品质,增加了发病率和死亡率,成为家庭与社会的沉重负担。糖尿病的高发生率对生活质量和医疗系统的经济成本都有重大影响,这是一个重大的公共卫生问题。
目前临床上应用于糖尿病的药物包括双胍类、磺酰脲类、噻唑烷二酮类、格列奈类、α-糖苷酶抑制剂类、GLP-1类似物、DDP-4抑制剂类和SGLT2抑制剂类药物。各药物存在包括副作用高、药效弱、继发性失效、价格昂贵等不同问题。α-糖苷酶抑制剂类药物的阿卡波糖在中国的口服糖尿病药物中占有最高的销售额和市场份额。该类药物可延缓碳水化合物的水解和吸收,从而降低餐后血糖并改善糖尿病。其用药具有安全性高,无继发性失效的特点。阿卡波糖的缺点在于降糖机制比较单一,未消化的碳水化合物会导致一定胃肠道副作用,并且价格略高于传统双胍类药物。
许多天然产物来源的提取物和单体化合物,也具有α-葡萄糖苷酶抑制或降低餐后血糖作用,其中也不乏效果强于上市药物的化合物。与常见的上市药物相比较,他们的副作用往往较小。因此,越来越多的大众消费和研究不断投入到天然药物的发现、评价与合成中。一些黄酮类化合物对α-葡萄糖苷酶的抑制作用,如杨梅素、槲皮素、山奈酚、非瑟酮、木犀草素、大豆苷元、染料木素的抑制作用已经被报道(Biotechnology,and Biochemistry,2000,64(11): 2458-2461),但因活性低于上市的阿卡波糖的药物,并未在临床上使用。
桑树是重要的药用植物资源,桑叶、桑椹、桑枝、桑白皮都含有特殊的物质和功能性成分,均可入药,具有独特的药用价值。桑树中具有活性的生物碱主要是多羟基生物碱中的哌啶烷类,该类生物碱与吡喃糖的结构类似,是吡喃糖环上的氧原子被氮原子取代而形成的一系列化合物。桑叶中含有丰富的生物碱,日本学者ASano等通过离子交换色谱从桑叶中分离出多种多羟基生物碱1- 脱氧野尻霉素(1-DNJ),也发现了N-甲基-1-DNJ,2-氧-α-D-半乳吡喃糖苷-1-DNJ (GAL-DNJ),荞麦碱(fagomine),1,4-二脱氧-1,4-亚氨D-阿拉伯糖醇(D-ABI) 等野尻霉素的衍生物,这类化合物具有较强强的α-葡萄糖苷酶抑制活性,具有降血糖功效。其中1-DNJ活性最好。但桑属植物中1-DNJ含量很低,只有约0.1 %(100mg/100g干品),1-DNJ的生物利用度也较差较低。尽管DNJ在体外具有良好的的α-葡萄糖苷酶抑制活性,但它的体内活性不佳,未能在临床上使用。 (沈阳药科大学学报,2000,17,456-460)。
药物的协同作用是药物发现的主要来源,虽然不同的协同作用的药物机理不尽相同,但人们已经可以选用一些方法评价药物的协同作用,例如,Chou等人提出了通过计算协同指数(CI,Combination index)的方式来评价药物之间的协同作用,这种计算模型既可以是适用于动物实验,也可以是适用于体外酶学、抑菌、细胞实验,并且对联用药物的剂量设置,没有十分苛刻的要求。根据药物间的协同、叠加和拮抗作用,药物相互作用计算出的CI值可以分为三个区间。其中协同作用CI<0.9;叠加作用0.9<CI<1.1;拮抗作用CI>1.1。而在评价药物协同作用的强弱时又可以将CI值分为几个区间,小于0.3为强协同;大于0.3 小于0.7为较强协同;大于0.7小于0.9为轻微协同。为评价药物协同作用的强弱,提供了一种有效评价方式。
对于作用机制比较复杂的糖尿病,人们已经开始使用开发各种具有协同作用的药物,两种针对II型糖尿病的联用药物Glucovance和Avandamet已经FDA 批准上市,分别是二甲双胍与格列本脲的联用和二甲双胍与罗格列酮的联用,可通过不同的糖代谢途径降低餐后血糖,但是无法避免糖尿病药物的继发性失效,且易导致患者低血糖。中国专利申请号201110201221.1公开了卷柏活性提取物和夏枯草活性提取物联用对酵母α-葡萄糖苷酶的协同抑制作用,但其针对的酶不是哺乳动物源的α-糖苷酶,而且化合物的成分和含量不明,未来使用中药物质量控制困难。据我们所知,目前尚多酚基苯乙酮类化合物协同抑制麦芽糖水解酶的报道。
在使用有机化合物进行小鼠麦芽糖酶筛选的研究中,我们惊奇地发现2,3,4- 三羟基苯乙酮(Gallacetophenone)具有抑制小鼠麦芽糖酶的活性,进一步发现该化合物还具有和1-DNJ协同抑制小鼠麦芽糖酶的作用,具有预防和治疗糖尿病的作用。2,3,4-三羟基苯乙酮是联苯三酚的衍生物,曾被作为染料的中间体,也曾被报道具有微弱的幽门螺杆菌脲酶的抑制活性(Journal of Natural Product 2001,64,368),但在糖尿病领域,特别是麦芽糖酶的抑制活性未见报道。
发明内容
本发明提供一种包括2,3,4-三羟基苯乙酮和1-脱氧野尻霉素的药物组合物,该组合物既能使联用药物间具有协同作用提升药效,并且药物组合物均为天然产物活性成分,副作用低,可降低餐后血糖,预防或治疗糖尿病及肥胖症。
本发明的技术目的通过以下技术方案实现:
一种具有麦芽糖水解酶抑制活性的药物组合物,包括2,3,4-三羟基苯乙酮和1-脱氧野尻霉素。
进一步地,所述黄酮类化合物和1-脱氧野尻霉素的混合比例按摩尔比为 200~30,000:1。其中更优选所述2,3,4-三羟基苯乙酮、其有机盐或其无机盐与 1-DNJ的混合比例按摩尔比为400~26000:1,最优选408~13042:1。
本发明的上述药物组合物中的任一技术方案,还包括药学上可接受的载体和/或赋形剂。其在药学上可接受的载体和/或赋形剂是一种或多种常用的填充剂、粘合剂、润湿剂、崩解剂、吸收促进剂、表面活性剂、吸附载体、润滑剂或矫味剂的载体。填充剂可选自淀粉、蔗糖、乳糖或微晶纤维素;粘合剂选自纤维素衍生物、藻酸盐、明胶或聚乙烯吡咯烷酮;崩解剂选自羧甲基淀粉钠、羟丙纤维素、交联羧甲基纤维素、琼脂、碳酸钙或碳酸氢钠;表面活性剂可以是十六烷醇或十二烷基硫酸钠;润滑剂选自滑石粉、硬脂酸钙、镁、微粉硅胶或聚乙二醇等。
本发明的另一目的在于提供一种包含上述任一所述的药物组合物的制药剂型,包括片剂、胶囊剂、滴丸剂或颗粒剂。
本发明的药物组合物的各种制药剂型可以按照药学领域的常规生产方法制备所需要的制剂。例如,片剂可为普通片、薄膜片、肠溶片等,可以用上述组合物干粉,加入适量稀释剂选自淀粉、糊精、甘露醇、微晶纤维素,适量的粘合剂选自水、乙醇、纤维素、淀粉、明胶,适量的崩解剂选自羧甲基淀粉钠、低取代羟丙基纤维素、海藻酸钠,以及适当的润滑剂选自硬脂酸镁、滑石粉、聚乙二醇,加入甜味剂,选自D-木糖、木糖醇、麦芽糖醇、甜叶菊素、天冬甜母,按常规湿法制粒,干燥后整粒或者干法制粒后压片,如为包薄膜衣片,用成膜材料选自纤维素类、聚乙二醇类,按常规包衣,分装入密闭瓶或者铝塑板中。胶囊剂可为普通胶囊剂、肠溶胶囊剂等,可将药物组合物干粉加入适当辅料选自碳酸钙、甘露醇、氧化镁、微粉硅胶等,适当润滑剂选自滑石粉、硬脂酸镁、乙二醇酯、聚硅酮类,以及适当的粘合剂选自矿物油、食油,并加入适当甜味剂,选自D-木糖、木糖醇、麦芽糖醇、甜叶菊素、天冬甜母,混合成干粉或者制成颗粒,填充入胶囊,分装在密闭瓶或者铝塑板中。
本发明所述的具有麦芽糖水解酶抑制活性的药物组合物可用于制备治疗糖尿病药物中,所述的糖尿病为I型糖尿病、II型糖尿病和糖尿病前期,所述α- 糖苷酶针对的底物为麦芽糖。
本发明另一目的是提供2,3,4-三羟基苯乙酮在制备治疗糖尿病药物中的应用,所述药物可进一步包含1-脱氧野尻霉素。
本发明的药物组合物可通过口服的方式施用于需要这种治疗的患者。
本发明的有益效果:
本发明提供了一种2,3,4-三羟基苯乙酮和1-脱氧野尻霉素的药物组合物,具有良好的降糖效果,可有效协同作用提升药效,减少单一化合物生物利用度低,代谢快的问题,无副作用。
因此,本发明的药物组合物能更有效的降低餐后血糖,能够抑制以麦芽糖和为底物麦芽糖水解酶活性,完全使用天然药物活性成分,因此可以提高药效,副作用低,而且还有效地解决了药物联用易引发低血糖等问题。
附图说明
图1是2,3,4-三羟基苯乙酮和1-脱氧野尻霉素的化学结构。
图2是2,3,4-三羟基苯乙酮与1-DNJ协同抑制小鼠小肠麦芽糖水解酶,Gallacetophenone为2,3,4-三羟基苯乙酮用量,1-DNJ为1-DNJ用量,图中数值为联用药物的CI值;
图3是2,3,4-三羟基苯乙酮与1-DNJ单用以及联用降低麦芽糖负荷小鼠餐后血糖升高OGTT实验(*p<0.05,#p<0.01);
图4是2,3,4-三羟基苯乙酮和1-DNJ单用以及联用降低麦芽糖负荷小鼠餐后血糖升高OGTT实验的曲线下面积(AUC)分析(*p<0.05)A.阴性对照组;B.0.4 mg/mL 1-DNJ组;C:60mg/mL 2,3,4-三羟基苯乙酮组;D:0.4mg/mL 1-DNJ和60mg/mL 2,3,4-三羟基苯乙酮联用组。
具体实施方式
下述非限制性实施例可以使本领域的普通技术人员更全面地理解本发明,但不以任何方式限制本发明。
本发明中使用的材料和方法:
材料:
本发明所使用的1-DNJ购于成都曼思特生物科技有限公司,纯度≥98%;2,3, 4-三羟基苯乙酮购于上海源叶生物科技有限公司公司,纯度≥98%;麦芽糖购于上海索莱宝生物科技有限公司。
方法:
抑制率的计算方法:
以小鼠小肠α-葡萄糖苷酶为酶源,以麦芽糖为底物,葡萄糖氧化酶法测定生成葡萄糖浓度,按照以下公式计算抑制剂单独或混合使用对酶的抑制率:
其中:
样品组(A):加入抑制剂后的吸光值
对照组(A):不加抑制剂,只加入对照缓冲液和酶的吸光值
以各药物单用、联用抑制率随剂量的变化做图,对比单用、联用间抑制率的差异。
协同指数的计算:
按Chou等人的理论,使用CompuSyn软件对联用药物在各个抑制率点上的协同指数(CI)进行计算。
其中:
(D)1:抑制剂1单用达到某特定药效所需剂量
(D)2:抑制剂2单用达到某特定药效所需剂量
(Dx)1:抑制剂联用达到某特定药效所需抑制剂1的剂量
(Dx)2:抑制剂联用达到某特定药效所需抑制剂2的剂量
如果CI小于0.9,则为协同作用;CI大于0.9小于1.1,则为叠加作用;CI 大于1.1,则为拮抗作用。在协同作用的范围内,CI值越小,协同作用越强。
下述实施例用于解释本发明。但是这些实施例绝非意欲限制本发明或其保护范围。这些实施例说明以本发明组合物所取得的协同关系。
实施例1小鼠小肠麦芽糖水解酶抑制活性测定方法
将昆明小鼠(20~23g)禁食16h,断颈处死后取小肠,剖开,用预冷的PBS (0.1M,pH7.0)缓冲液冲洗,后按照1:10(W/V)加入PBS缓冲液。将小肠剪成碎段后匀浆,4℃,10000r/min,离心15min,取上清液作为试验用α-葡萄糖苷酶母液。
酶反应体系总体积为250μL,包括酶液、2,3,4-三羟基苯乙酮、1-DNJ、麦芽糖、缓冲液各50μL,其中2,3,4-三羟基苯乙酮溶解于50%DMSO。首先将酶与两种抑制剂混匀,37℃温育30min,加入50μL麦芽糖溶液启动反应。37℃温育,反应20min。样品置于沸水中5min,以终止反应。使用葡萄糖氧化酶试剂盒测定生成葡萄糖浓度,待样品冷却,各取5μL,加入200μL葡萄糖氧化酶工作液中于96孔板。充分混匀后37℃反应15min。酶标仪505nm下测定样品吸光值,计算抑制率和CI值。
实施例2 2,3,4-三羟基苯乙酮单用以及和1-DNJ联用对小鼠小肠麦芽糖水解酶的抑制
1-DNJ单独使用时,在0.023~0.184μM范围内,对麦芽糖水解酶的抑制率从28.7%增至55%(图1)。单独使用2,3,4-三羟基苯乙酮,浓度从75增加到600 μM时,对麦芽糖水解酶的抑制率从28.2%增加至45%,显示对抑制活性小鼠小肠麦芽糖水解酶也具有抑制活性。但75、150、300和600μM2,3,4-三羟基苯乙酮分别与0.023、0.046、0.092、0.184μM 1-DNJ联用,在各个剂量点上联用抑制率较单用抑制率均有明显提高,CI值分别为在0.27~0.96之间(表1),其中典型的CI值如图2所示,结果表明2,3,4-三羟基苯乙酮与1-DNJ联用对于麦芽糖水解酶水解麦芽糖的过程具有较强的协同抑制作用,特别是在2,3,4-三羟基苯乙酮高浓度时,作用更佳明显。
表1.2,3,4-三羟基苯乙酮与1-DNJ协同抑制小鼠小肠麦芽糖水解酶的CI指数
实施例3 2,3,4-三羟基苯乙酮与1-DNJ联用降低麦芽糖负荷小鼠餐后血糖升高
使用18-23g C57小鼠(雄性),饲养5d使其稳定。给药前禁食不禁水16h,麦芽糖灌胃浓度为2g/kg。将麦芽糖与药物混合物以灌胃方式给药,灌胃溶液体积为0.2mL/20g。断尾取血,血糖仪测定给药0、30、60、90、120min血糖值。
1-DNJ单用组配置浓度为0.4mg/mL的1-DNJ;2,3,4-三羟基苯乙酮单用组灌胃60mg/mL的2,3,4-三羟基苯乙酮;联用组为0.4mg/mL的1-DNJ和60 mg/mL的2,3,4-三羟基苯乙酮的联用,阴性对照组只灌胃麦芽糖。如图3所示,将0.4mg/mL的1-DNJ和60mg/mL的2,3,4-三羟基苯乙酮联用,餐后30min 血糖值与相应2,3,4-三羟基苯乙酮和1-DNJ单用相比均有显著降低(p<0.05),比较其曲线下面积(AUC)也可看出,联用组(D组)曲线下面积和1-DNJ单用组(B组)及2,3,4-三羟基苯乙酮组(C组)相比显著降低(p<0.05)(图4),表明联用组能够维持餐后血糖的平稳,降低麦芽糖负荷的餐后血糖,发挥治疗糖尿病的作用。同时联用给药组,无论是麦芽糖负荷前和负荷后,血糖值均高于4,即未出现低血糖的现象。
Claims (6)
1.2, 3, 4-三羟基苯乙酮和1-脱氧野尻霉素的组合在制备治疗糖尿病的药物中的应用,其特征在于2, 3, 4-三羟基苯乙酮和1-脱氧野尻霉素的混合比例按摩尔比为200:1~(75:0.046):1。
2.根据权利要求1所述的应用,其特征在于所述的糖尿病为I型糖尿病、II型糖尿病或糖尿病前期。
3.根据权利要求1所述的应用,其特征在于所述药物组合物通过抑制麦芽糖酶活性来治疗糖尿病。
4.一种具有麦芽糖酶抑制活性的药物组合物,其特征在于包括:2, 3, 4-三羟基苯乙酮和1-脱氧野尻霉素,且2, 3, 4-三羟基苯乙酮和1-脱氧野尻霉素的混合比例按摩尔比为200:1~(75:0.046):1。
5.根据权利要求4所述的具有麦芽糖酶抑制活性的药物组合物,其特征在于:还包括药学上可接受的载体和/或赋形剂。
6.一种包含权利要求4~5任意一项所述的具有麦芽糖抑制活性药物组合物的制药剂型,其特征在于:所述剂型为片剂、胶囊剂、滴丸剂或颗粒剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010530261.XA CN111643490B (zh) | 2020-06-11 | 2020-06-11 | 一种具有麦芽糖水解酶抑制活性的药物组合物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010530261.XA CN111643490B (zh) | 2020-06-11 | 2020-06-11 | 一种具有麦芽糖水解酶抑制活性的药物组合物及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111643490A CN111643490A (zh) | 2020-09-11 |
CN111643490B true CN111643490B (zh) | 2023-04-07 |
Family
ID=72349072
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010530261.XA Active CN111643490B (zh) | 2020-06-11 | 2020-06-11 | 一种具有麦芽糖水解酶抑制活性的药物组合物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111643490B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109925305A (zh) * | 2018-12-24 | 2019-06-25 | 西北农林科技大学 | 苯乙酮类衍生物制备糖苷酶抑制剂/糖尿病药物的应用 |
CN111228267A (zh) * | 2020-02-28 | 2020-06-05 | 大连理工大学 | 一种具有麦芽糖水解酶抑制活性的药物组合物及其应用 |
-
2020
- 2020-06-11 CN CN202010530261.XA patent/CN111643490B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109925305A (zh) * | 2018-12-24 | 2019-06-25 | 西北农林科技大学 | 苯乙酮类衍生物制备糖苷酶抑制剂/糖尿病药物的应用 |
CN111228267A (zh) * | 2020-02-28 | 2020-06-05 | 大连理工大学 | 一种具有麦芽糖水解酶抑制活性的药物组合物及其应用 |
Non-Patent Citations (3)
Title |
---|
Dietary 5,6,7-Trihydroxy-flavonoid Aglycones and 1-Deoxynojirimycin Synergistically Inhibit the Recombinant Maltase-Glucoamylase Subunit of α-Glucosidase and Lower Postprandial Blood Glucose;Yuesheng Dong等;《Journal of Agricultural and Food Chemistry》;20200730;8774-8787 * |
淡文佳.苯乙酮衍生物的合成、生物活性及作用机制研究.《工程科技Ⅰ辑》.2019,B014-89. * |
苯乙酮衍生物的合成、生物活性及作用机制研究;淡文佳;《工程科技Ⅰ辑》;20190831;B014-89 * |
Also Published As
Publication number | Publication date |
---|---|
CN111643490A (zh) | 2020-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107812193B (zh) | 一种具有α-糖苷酶抑制活性的药物组合物及其应用 | |
EP3666267B1 (en) | Combination product containing a limonoid compound and metformin | |
CN101590007A (zh) | 一种盐酸二甲双胍/伏格列波糖降糖口服制剂组合物及其制备 | |
WO2012041898A1 (en) | Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes | |
CN110898025A (zh) | 阿卡波糖缓释制剂及其制备方法 | |
KR20140008452A (ko) | 진성 당뇨병을 치료하기 위한 병용제 | |
EP4014978B1 (en) | Combination product containing a limonoid compound and acarbose | |
EP4014998B1 (en) | Combination product comprising limonoid and dpp-4 inhibitors | |
EP4014999B1 (en) | Combination product containing limonin compound and sulfonylurea drug | |
CN101121004B (zh) | 含有胰岛素增敏剂和米格列醇的药物组合物 | |
KR100709528B1 (ko) | 혈당콘트롤용 의약조성물 | |
CN111643490B (zh) | 一种具有麦芽糖水解酶抑制活性的药物组合物及其应用 | |
US6509035B1 (en) | Oral preparation of coenzyme a useful for lowering blood lipid and a method producing for same | |
CN107349210B (zh) | 具有α-淀粉酶协同抑制活性的组合物 | |
CN111228267B (zh) | 一种具有麦芽糖水解酶抑制活性的药物组合物及其应用 | |
CN102727894A (zh) | 一种治疗糖尿病及其并发症的药物组合物及其应用 | |
JP2022544295A (ja) | リモノイド化合物およびsglt-2阻害剤を含有する組合せ製品 | |
CN111195247B (zh) | 一种α-葡萄糖苷酶抑制剂及其在降血糖药物中的应用 | |
CN101198326A (zh) | Ⅱ型糖尿病治疗用的组合药物制剂 | |
CN104840480B (zh) | 二甲双胍/叶酸/维生素b12药物组合物的新用途 | |
CN113304139B (zh) | Viniferifuran在制备黄嘌呤氧化酶抑制药物中的应用 | |
CN102408459A (zh) | 一类含异头位烷基的苯基c-葡萄糖苷衍生物、其制备方法和用途 | |
US20230346817A1 (en) | Composition and use of sglt-2 inhibitor and angiotensin receptor blockers | |
CN114886885A (zh) | 一种具有抑制糖异生作用的药物组合物及其应用 | |
TWI723171B (zh) | 一種多醣混合物用於製備高血糖症藥物的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: Room 409, 4th Floor, Building 1, No. 38 Yongda Road, Daxing Biopharmaceutical Industry Base, Zhongguancun Science and Technology Park, Daxing District, Beijing 102600 (cluster registration) Patentee after: Beijing Gaoyu Pharmaceutical Technology Co.,Ltd. Address before: 202172 room 111-13, 4 building, 700 Xing Village Road, Xinhai Town, Chongming District, Shanghai (Shanghai Xinhai Economic Development Zone) Patentee before: Shanghai Gao Yu Medicine Technology Co.,Ltd. |